The Treat-JIANCT07904780
Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis
StatusNot Yet Recruiting
PhasePhase 4
SponsorOslo University Hospital
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Secondary endpoints revised (8)
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Proportion of disease flare
Timeframe: 4, 8 and 12 months
Secondary (8)
Time to disease flare
Time to regain inactive disease after flare
Incidence of adverse events, serious adverse events and suspected unexpected serious adverse reactions
Physician global assessment of disease activity
Patient's/parent's global assessment of well-being
Show 3 moreShow less
Active joint count
Erythrocyte sedimentation rate (ESR)
Childhood Health Assessment Questionnaire (CHAQ)
Arms and interventions
Stable TNF-inhibitor monotherapyActive comparator
Continued TNF-inhibitor therapy at a stable dose. This can be adalimumab, etanercept or golimumab.
TNF-inhibitor withdrawalExperimental
Doubled treatment interval of the TNF-inhibitor therapy for 4 months, then subsequent withdraw of the TNF-inhibitor therapy.
Drugs: Adalimumab, Etanercept, Golimumab
Sites
3 sites in 1 country